These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33384041)

  • 1. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
    Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
    Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
    J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
    Garcia-Prats AJ; Schaaf HS; Hesseling AC
    Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
    Hong H; Budhathoki C; Farley JE
    Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
    Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
    Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
    Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
    BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    Rev Soc Bras Med Trop; 2017; 50(5):646-651. PubMed ID: 29160511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.
    Modongo C; Sobota RS; Kesenogile B; Ncube R; Sirugo G; Williams SM; Zetola NM
    BMC Infect Dis; 2014 Oct; 14():542. PubMed ID: 25300708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
    Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
    Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.
    Cegielski JP; Chan PC; Lan Z; Udwadia ZF; Viiklepp P; Yim JJ; Menzies D
    Clin Infect Dis; 2021 Dec; 73(11):e3929-e3936. PubMed ID: 33124668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB).
    Sabur NF; Brar MS; Wu L; Brode SK
    BMC Infect Dis; 2021 Mar; 21(1):254. PubMed ID: 33691624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.
    Javadi MR; Abtahi B; Gholami K; Safari Moghadam B; Tabarsi P; Salamzadeh J
    Iran J Pharm Res; 2011; 10(4):905-11. PubMed ID: 24250429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    J Bras Pneumol; 2018 Apr; 44(2):85-92. PubMed ID: 29791559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
    Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
    Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.